Saved in:
Bibliographic Details
Main Authors: Manzhulo, Igor, Egoraeva, Anastasia, Ivashkevich, Darya, Manzhulo, Olga, Ponomarenko, Arina
Format: Artículo científico
Language:en
Published: Inflammopharmacology 2025
Subjects:
Online Access:https://pubmed.ncbi.nlm.nih.gov/40617897/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1868266181669945345
author Manzhulo, Igor
Egoraeva, Anastasia
Ivashkevich, Darya
Manzhulo, Olga
Ponomarenko, Arina
author_facet Manzhulo, Igor
Egoraeva, Anastasia
Ivashkevich, Darya
Manzhulo, Olga
Ponomarenko, Arina
Manzhulo, Igor
Egoraeva, Anastasia
Ivashkevich, Darya
Manzhulo, Olga
Ponomarenko, Arina
collection PubMed - marine biology
contents Synaptamide regulates astroglial functional activity after cerebral cortex injury. Manzhulo, Igor Egoraeva, Anastasia Ivashkevich, Darya Manzhulo, Olga Ponomarenko, Arina Animals Astrocytes Mice Cerebral Cortex Male Brain Injuries, Traumatic Ethanolamines Gliosis Neuroprotective Agents Mice, Inbred C57BL Brain-Derived Neurotrophic Factor Modern approaches to the treatment of traumatic brain injury (TBI) focus on alleviating life-threatening conditions. However, background glial activation processes occurring throughout the brain are often overlooked and may contribute to long-term damage and cognitive decline in patients with TBI. Currently, there is increasing evidence to support the influence of endogenous lipid messengers such as N-acylethanolamines fatty acids in neuropathologies. Synaptamide (N-docosahexaenoylethanolamine) plays an important role in brain repair after neurotrauma due to its significant anti-inflammatory, gliotropic and neuroprotective effects. The aim of this study was to investigate the processes of reactive astrogliosis occurring in two brain regions (cortex and thalamus) following cerebral cortex injury and synaptamide therapy (10 mg/kg/day, 7 days) in mice. Synaptamide was shown to reduce the expression of brain damage biomarkers in the blood, inhibit the development of reactive astrogliosis, and trigger the activation of anti-inflammatory A2 type reactive astrocytes, with the synthesis of the main brain neurotrophins (Clcf1, BDNF) in vitro and in vivo. The therapeutic efficacy of synaptamide demonstrated in this study makes it a promising drug for the treatment of TBI.
format Artículo científico
id pubmed_40617897
institution PubMed
language en
publishDate 2025
publisher Inflammopharmacology
record_format pubmed
spellingShingle Synaptamide regulates astroglial functional activity after cerebral cortex injury.
Manzhulo, Igor
Egoraeva, Anastasia
Ivashkevich, Darya
Manzhulo, Olga
Ponomarenko, Arina
Animals
Astrocytes
Mice
Cerebral Cortex
Male
Brain Injuries, Traumatic
Ethanolamines
Gliosis
Neuroprotective Agents
Mice, Inbred C57BL
Brain-Derived Neurotrophic Factor
Synaptamide regulates astroglial functional activity after cerebral cortex injury. Manzhulo, Igor Egoraeva, Anastasia Ivashkevich, Darya Manzhulo, Olga Ponomarenko, Arina Animals Astrocytes Mice Cerebral Cortex Male Brain Injuries, Traumatic Ethanolamines Gliosis Neuroprotective Agents Mice, Inbred C57BL Brain-Derived Neurotrophic Factor Modern approaches to the treatment of traumatic brain injury (TBI) focus on alleviating life-threatening conditions. However, background glial activation processes occurring throughout the brain are often overlooked and may contribute to long-term damage and cognitive decline in patients with TBI. Currently, there is increasing evidence to support the influence of endogenous lipid messengers such as N-acylethanolamines fatty acids in neuropathologies. Synaptamide (N-docosahexaenoylethanolamine) plays an important role in brain repair after neurotrauma due to its significant anti-inflammatory, gliotropic and neuroprotective effects. The aim of this study was to investigate the processes of reactive astrogliosis occurring in two brain regions (cortex and thalamus) following cerebral cortex injury and synaptamide therapy (10 mg/kg/day, 7 days) in mice. Synaptamide was shown to reduce the expression of brain damage biomarkers in the blood, inhibit the development of reactive astrogliosis, and trigger the activation of anti-inflammatory A2 type reactive astrocytes, with the synthesis of the main brain neurotrophins (Clcf1, BDNF) in vitro and in vivo. The therapeutic efficacy of synaptamide demonstrated in this study makes it a promising drug for the treatment of TBI.
title Synaptamide regulates astroglial functional activity after cerebral cortex injury.
topic Animals
Astrocytes
Mice
Cerebral Cortex
Male
Brain Injuries, Traumatic
Ethanolamines
Gliosis
Neuroprotective Agents
Mice, Inbred C57BL
Brain-Derived Neurotrophic Factor
url https://pubmed.ncbi.nlm.nih.gov/40617897/